The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient.
Berecek
Kathleen H
KH
Department of Physiology and Biophysics, University of Alabama at Birmingham, 35294, USA. berecek@uab.edu
Farag
Amal
A
Bahtiyar
Gul
G
Rothman
Jeffery
J
McFarlane
Samy I
SI
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D000960:Hypolipidemic Agents